The short answer
Coverage turns on three things: whether Zepbound is on your plan's formulary at all, whether your prescriber's prior authorisation packet matches the plan's written criteria, and whether you use the appeal rights you already have if it is denied. Most people stop at the first denial, which is where the leverage actually begins. Under federal rules you have 180 days to file an internal appeal, the insurer must decide within 30 days for a service you have not yet received, and if that fails you have 4 months to request an independent external review, whose decision the insurer is required by law to accept. There is also a second route most guides miss entirely: Zepbound carries two approved indications, and a plan that excludes weight-loss drugs may still cover the other one.
The second indication, and why it matters first
Before the paperwork, check the premise. Zepbound's prescribing information lists two indications: reducing excess body weight and maintaining weight reduction in adults with obesity or overweight with a weight-related comorbid condition, and treating moderate to severe obstructive sleep apnoea in adults with obesity. The FDA approved that second indication on 20 December 2024, describing it as the first medication approved for obstructive sleep apnoea.
This matters because a large share of denials are not clinical judgements at all. They are category exclusions: the plan simply does not cover drugs for weight loss. An exclusion written against weight-management drugs does not automatically dispose of a request made under a different, separately approved indication. If you have diagnosed moderate to severe obstructive sleep apnoea, that is a conversation to have with your prescriber before you spend three months appealing on the weight-management pathway. We cannot tell you whether it applies to you, and a sleep study is a clinical matter, but it is the question most worth asking early.
Step 1: find out what your plan actually requires
Ask the insurer, not the internet. Call the member number on your card and ask three specific questions, writing down the answers and the reference number for the call:
- Is Zepbound on the formulary, and at what tier?
- Is there a weight-management drug exclusion on this plan, and does it apply to the obstructive sleep apnoea indication?
- Can you send me the written prior authorisation criteria for this drug?
That third request is the important one. Plans publish criteria, and a prior authorisation written against the actual criteria succeeds far more often than one written from a template. Criteria vary by plan, which is exactly why no article can tell you what yours are.
Step 2: build the packet to match the criteria
Prior authorisation is submitted by your prescriber, but the evidence mostly lives with you. Commonly requested elements across plans include BMI documentation, a weight-related condition, a record of previous supervised weight-management attempts, current medications and recent labs. The gap that sinks requests is almost always documentation of history rather than disagreement about the medicine.
| What plans commonly ask for | Who holds it | How it goes missing |
|---|---|---|
| Current BMI and weight history | Your prescriber's chart | Weights recorded inconsistently or at another practice |
| A weight-related comorbid condition | Diagnosis codes in the chart | The condition is managed but never formally coded |
| Documented prior weight-management attempts | You, plus the chart | The attempts happened but were never written down anywhere |
| Step therapy: a trial of a preferred alternative | Pharmacy claims history | Tried and abandoned without the outcome being recorded |
| Evidence of ongoing adherence and engagement | You | Nobody asked you to keep a record, so there is none |
| Sleep study results, if using the OSA indication | Sleep clinic | Never requested because the weight pathway was assumed |
Two of those rows are things only you can supply. A dated record of what you have tried, and a record of how consistently you have taken what you were prescribed, are the two pieces of evidence that are routinely absent and routinely decisive. If you are already on treatment and appealing a continuation denial, an export of your own dose history is genuinely useful documentation, and it costs nothing to have been keeping it.
Step 3: the appeal deadlines, which are not negotiable
This is the section almost every competing guide gets vague about, quoting "3 to 7 days" or "3 to 21 days" from unclear sources. The federal timeframes are published and specific.
| Stage | Your deadline | Their deadline | Binding? |
|---|---|---|---|
| Internal appeal, service not yet received | 180 days (6 months) from the denial notice | Completed within 30 days | It is the insurer's own review |
| Internal appeal, service already received | 180 days from the denial notice | Completed within 60 days | Insurer's own review |
| Expedited internal appeal, urgent | As soon as you have the denial | As fast as the condition requires, and within 4 business days of the request; a verbal decision confirmed in writing within 48 hours | Insurer's own review |
| External review, standard | 4 months from the final internal denial | Decision no later than 45 days after the request is received | Yes. The insurer is required by law to accept the external reviewer's decision |
| External review, expedited | Immediately, on medical urgency | Decision in 72 hours or less, depending on urgency | Yes |
The part people do not know
External review is decided by an independent third party, not by the insurer, and the result is binding on the insurer by law. A plan that has denied you twice does not get to decide the third time. This is a federal consumer right, free to use, and it is the reason the first denial is not the end of the process.
Step 4: match the response to the reason
Ask the insurer for the specific reason in writing before you respond. The reason determines what you send back, and sending the wrong thing wastes one of your rounds.
| Stated reason | What it actually means | The response that fits |
|---|---|---|
| Not on formulary | A coverage design decision, not a clinical one | A formulary exception request, with the prescriber's rationale for why alternatives are unsuitable |
| Plan excludes weight-loss drugs | A category exclusion | Check whether the obstructive sleep apnoea indication applies, and whether the exclusion is written to cover it |
| Criteria not met, BMI or comorbidity | The documentation did not arrive, or did not say what was needed | Resubmit with the chart evidence against each written criterion, point by point |
| Step therapy not satisfied | They want a preferred alternative tried first | Document a previous trial and its outcome, or ask the prescriber to request a step therapy exception on clinical grounds |
| Not medically necessary | A clinical disagreement | Ask the prescriber to request a peer-to-peer review with the insurer's medical director, then escalate to external review |
| Insufficient documented prior attempts | The history exists but is not in writing | Dated records of what you tried, for how long, and what happened |
Keeping the record that the packet needs
Two of the six response types above are satisfied with dated records rather than clinical argument. Adherence and documented attempts are the two things a plan asks about and that nobody thinks to capture until the denial letter arrives, at which point reconstructing eighteen months from memory is the task.
If you are on treatment now, logging each injection as you go produces that documentation as a by-product. For a continuation denial in particular, a dose history showing consistent weekly administration is directly responsive to the question being asked. Jabby keeps dose dates, sites and side effects on one timeline, and the export is the thing you hand to the prescriber's office when they are assembling the packet.
Have the record before you need it
Log every dose as you go. Reconstructing a year of adherence after a denial letter is the hard way.
Download Jabby - Free on App StoreFrequently asked questions
How long does Zepbound prior authorisation take?
Initial prior authorisation turnaround is set by your plan and state law rather than by a single federal number, which is why published estimates vary so widely. The timeframes that are federally specified apply to appeals: a standard internal appeal of a service not yet received must be completed within 30 days, an urgent one within 4 business days, and a standard external review within 45 days.
What do I do if Zepbound is denied?
Get the specific reason in writing, then file an internal appeal within 180 days of the denial notice. If the internal appeal fails, request an external review within 4 months of the final internal denial. The external reviewer is independent and the insurer is required by law to accept its decision.
Can I appeal if my plan excludes weight-loss drugs entirely?
A blanket category exclusion is the hardest denial to overturn, because it is a term of the plan rather than a clinical judgement. The two things worth checking are whether a different approved indication falls outside the exclusion as written, and whether an employer-sponsored plan can be asked to reconsider the exclusion at renewal. Ask for the exclusion language itself in writing.
Does Medicare cover Zepbound?
Medicare coverage of weight-management drugs is governed by rules distinct from commercial plans, and the federal internal appeal and external review process described here is the one that applies to private and Marketplace plans. Medicare has its own multi-level appeals process. Check your specific plan documents, and note separately that Lilly's savings card excludes government beneficiaries entirely.
What is a peer-to-peer review?
Your prescriber speaks directly with a clinician at the insurer about the case. It is usually quick to arrange, it does not consume your formal appeal rights, and it is worth requesting for a "not medically necessary" denial before the written appeal, because a clinical disagreement is often faster to resolve clinician to clinician.
Can I use the manufacturer savings card while I appeal?
The Zepbound savings card requires commercial insurance, and there are separate tiers for plans that cover the drug and plans that do not. Government beneficiaries are excluded. If you are paying out of pocket while an appeal runs, our guide to self-pay tirzepatide pricing sets out the manufacturer's published cash prices by dose.
Related guides
- Cheapest tirzepatide without insurance: manufacturer self-pay prices by dose while an appeal runs
- Zepbound maintenance dose after goal weight: what continuation looks like, which continuation denials turn on
- Not losing weight on Zepbound 15 mg: the trial benchmarks a reviewer may be weighing response against
- GLP-1 tracker app: keeping the dose record a prior authorisation packet asks for
Sources
- HealthCare.gov. Internal appeals. Read 8 October 2026. Source for: filing within 180 days (6 months) of the denial notice; completion within 30 days for a service not yet received and 60 days for one already received; urgent decisions within 4 business days with written confirmation of a verbal decision within 48 hours.
- HealthCare.gov. External review. Read 8 October 2026. Source for: filing within 4 months of the final internal denial; a standard decision no later than 45 days after the request is received; an expedited decision within 72 hours or less; and that the insurer is required by law to accept the external reviewer's decision.
- US Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea, 20 December 2024. Source for: the approval of Zepbound for moderate to severe obstructive sleep apnoea in adults with obesity, and the date.
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection prescribing information. Read 8 October 2026. Source for: both approved indications as written in the label.
- Eli Lilly and Company. Zepbound Coverage, Affordability and Savings. Read 8 October 2026. Source for: the savings card requiring commercial insurance and excluding government beneficiaries including Medicare and Medicaid enrollees.
This page is information, not medical, legal or insurance advice. Coverage criteria, formularies and exclusions are set by your specific plan and your plan documents take precedence over anything described here. The federal appeal timeframes cited apply to private and Marketplace plans; other programmes have their own processes. Clinical decisions, including whether any indication applies to you, belong to your prescriber.